Novo Nordisk lays off manufacturers of Ozempic in the USA: reasons for the cuts

According to glavcom.ua: The pharmaceutical giant Novo Nordisk, producer of popular weight loss and diabetes drugs Wegovy and Ozempic, has laid off dozens of employees at its largest manufacturing facility in the USA. This is part of the previously announced global restructuring. According to a review of LinkedIn posts, the cuts first affected staff directly involved in production. This was reported by

Glucom

citing Reuters.

An analysis of 73 posts and profiles showed that the layoffs affected staff in manufacturing positions, including quality control, production line technicians, and project coordinators, a strategic communications manager, and a personnel assistant. 47 laid-off employees directly published job-seeking announcements.

The publication notes that these layoffs, although a small fraction of the nine thousand planned cuts worldwide (most of which are in Denmark), highlight that Novo Nordisk is reducing even production at the forefront of its key market.

Novo Nordisk has cut production in the USA due to global restructuring, which has led to the layoff of dozens of employees. The laid-off employees were engaged in manufacturing positions, indicating cuts even in the manufacturing sector in the company's key market.